Proactive Investors - Run By Investors For Investors

AdAlta manufacturing pulmonary fibrosis candidate in next quarter

AdAlta Limited (ASX: 1AD) CEO Sam Cobb sat down with Christine Corrado at the Biotech Showcase in San Francisco.

AdAlta is an Australian public biotechnology company focused on the development and commercialisation of its i-body technology platform that has generated a pipeline of i-bodies, with an initial focus on treating fibrotic diseases. 

View full 1AD profile View Profile

Adalta Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use